Core Concepts
Neoadjuvant pembrolizumab plus chemotherapy shows promise in treating clinical stage III NSCLC.
Abstract
Standalone Note here
Abstract and Introduction
Pembrolizumab's effectiveness in preoperative stage III NSCLC is under evaluation.
Study conducted on 25 patients receiving neoadjuvant pembrolizumab plus chemotherapy.
Majority of patients underwent surgical resection post-induction therapy.
Neoadjuvant treatment regimen detailed with positive outcomes in terms of pathological response.
Results
Patients aged 65 on average, with a majority being men.
Majority diagnosed as clinical stage IIIA before treatment.
21 patients underwent surgical resection post-induction therapy.
Major pathological response (MPR) achieved in 13 patients, with 6 achieving complete pathological response (CPR).
Adverse events did not cause surgery delays or deaths.
Conclusions
Neoadjuvant pembrolizumab plus chemotherapy is considered reliable for clinical stage III NSCLC.
Calls for further validation through robust clinical trials.
Introduction
Lung cancer, particularly NSCLC, is a leading cause of global mortality.
Neoadjuvant chemotherapy followed by surgical resection is standard for resectable NSCLC.
Immune checkpoint inhibitors (ICIs) have shown promise in early-stage NSCLC treatment.
Pembrolizumab, an ICI, has demonstrated efficacy in advanced NSCLC but requires further analysis as a neoadjuvant drug.
Stats
Seventeen patients diagnosed as clinical stage IIIA before treatment.
Major pathological response (MPR) achieved in 13 patients.
Complete pathological response (CPR) rate of 28.6%.
Two patients with partial radiologic remission refused operative treatment.
Quotes
"Neoadjuvant pembrolizumab plus chemotherapy could be considered reliable for clinical stage III NSCLC."
"Pembrolizumab's capacity as a neoadjuvant drug in NSCLC has not been well analyzed."